EXEL vs MRK
Exelixis vs Merck & Co. — AI-powered side-by-side comparison
| Metric | EXEL | MRK |
|---|
| AI Score |
67
|
70
|
| Price |
$51.30
|
$130.34
|
| P/E Ratio |
15.60×
|
103.53×
|
| ROE |
36.2%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
75.4%
|
| Debt / Equity |
0.09×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
41.0
|
64.5
|
| Beta |
0.422
|
0.207
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus MRK.
MRK leads by 3 points.
MRK scores 70/100 (Buy) versus EXEL at 67/100 (Buy).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical